We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome (AReMIS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01952392
First Posted: September 30, 2013
Last Update Posted: February 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
August 21, 2013
September 30, 2013
February 24, 2017
October 2013
March 2016   (Final data collection date for primary outcome measure)
  • Medical information [ Time Frame: At baseline visit ]
    History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors
  • Drug exposure [ Time Frame: Current ]
    Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
  • Drug exposure [ Time Frame: Recent ]
    Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
  • Drug exposure [ Time Frame: Past ]
    Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
Same as current
Complete list of historical versions of study NCT01952392 on ClinicalTrials.gov Archive Site
Other medical events of interest [ Time Frame: During follow-up (up to 12 months) ]
rMI, stroke, bleeding, death
Same as current
Not Provided
Not Provided
 
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients aged 18 years or more, both genders,with an acute coronary syndrome, agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.
Acute Coronary Syndrome
Not Provided
  • Control group
    Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
  • Case group
    Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4992
March 2016
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.

No Exclusion Criteria.

Sexes Eligible for Study: All
18 Years to 130 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01952392
NIS-CFR-BRI-2012/1
Not Provided
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
February 2017